We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01228344
First Posted: October 26, 2010
Last Update Posted: April 7, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Centers for Disease Control and Prevention
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
October 19, 2010
October 26, 2010
April 7, 2017
May 1, 2010
September 30, 2015   (Final data collection date for primary outcome measure)
Effectiveness: Resolution of clinical signs and symptoms after artemether-lumefantrine treatment start [ Time Frame: 4 weeks ]
Same as current
Complete list of historical versions of study NCT01228344 on ClinicalTrials.gov Archive Site
  • Adverse event, serious adverse event after artemether-lumefantrine treatment start [ Time Frame: 4 weeks ]
  • Pregnancies after artemether-lumefantrine treatment start [ Time Frame: Up to delivery ]
Same as current
Not Provided
Not Provided
 
Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria
Surveillance for the Effectiveness and Safety of Artemether-lumefantrine in Pediatric and Adult Patients With Malaria
The purpose of this study is to describe the pediatric and adult patients (U.S. and foreign residents) diagnosed with malaria and treated with artemether-lumefantrine with regard to their demographics, including evaluation of their malaria immune status, treatment effectiveness, prior and concomitant medication use, and the occurrence of adverse events in association with artemether-lumefantrine treatment, based on the information collected in the CDC Malaria Case Surveillance Report Form.
Not Provided
Observational
Observational Model: Other
Time Perspective: Other
Not Provided
Not Provided
Non-Probability Sample
Any male or female infant, child or adult patient diagnosed with malaria who received artemether-lumefantrine and was reported to the Centers for Disease Control, Atlanta GA.
Malaria
Other: Artemether-lumefantrine
Artemether-lumefantrine
Intervention: Other: Artemether-lumefantrine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
324
September 30, 2015
September 30, 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Any male or female infant, child or adult patient diagnosed with malaria who received artemether-lumefantrine and was reported to the CDC. Malaria may be clinically suspected or confirmed (microscopically, and/or by polymerase chain reaction [PCR], and/or rapid diagnostic test [RDT]).

Exclusion Criteria:

Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01228344
CCOA566A2424
Not Provided
Not Provided
Not Provided
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Centers for Disease Control and Prevention
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
April 2017